AR and Familial prostate cancer: Currently, the PROTACs ARV-471 and ARV-110 are involved in clinical trials for their use as estrogen receptor (breast cancer) degraders and androgen receptor (prostate cancer) degraders, respectively (Neklesa et al., 2018; Flanagan et al., 2019).